Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Clinical trials  




2 See also  




3 References  













Mapracorat






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Mapracorat
Clinical data
Routes of
administration		Topical (ointment, eye drops)
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers

  • (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol

CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.217.969 Edit this at Wikidata
Chemical and physical data
FormulaC25H26F4N2O2
Molar mass462.489 g·mol−1
3D model (JSmol)

  • c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C

  • InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1 ☒N

  • Key:VJGFOYBQOIPQFY-XMMPIXPASA-N ☒N

 ☒NcheckY (what is this?)  (verify)

Mapracorat (INN, code names BOL-303242-X, ZK-245186[1]) is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis,[2] inflammation following cataract surgery,[3] and allergic conjunctivitis.[4] Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models.[1]

Clinical trials[edit]

Phase II clinical trials with mapracorat started in summer 2009. One trial was a double blind dose finding study for an ointment against atopic dermatitis. It tested concentrations of 0.01%, 0.03% and 0.1% versus placebo over four weeks in around 64 patients. This trial was conducted by Intendis, a part of Bayer HealthCare Pharmaceuticals specialized on dermatology, and completed in September or October 2010.[2] The other trial, also with a double blind design, evaluated an ophthalmic suspension for the treatment of inflammation following cataract surgery. Various concentrations and dosing schemes were tested versus placebo in about 550 patients. The study was conducted by Bausch & Lomb and completed in September 2010.[3] Its successor study, a phase III trial, started in November 2010 and completed in August 2011.[5]

As of January 2017 no study results are available.

See also[edit]

References[edit]

  1. ^ a b Cavet ME, Harrington KL, Ward KW, Zhang JZ (September 2010). "Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells". Molecular Vision. 16: 1791–800. PMC 2932489. PMID 20824100.
  • ^ a b Clinical trial number NCT00944632 for "Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis" at ClinicalTrials.gov
  • ^ a b Clinical trial number NCT00905450 for "Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01289431 for "Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis" at ClinicalTrials.gov
  • ^ Clinical trial number NCT01230125 for "Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery" at ClinicalTrials.gov
    • Stub icon

    This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

  • t
  • e
    • Stub icon

    This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e
    • Stub icon

    This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Mapracorat&oldid=1135125545"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Anti-inflammatory agents
     ●Benzofurans
     ●Fluoroarenes
     ●Immunosuppressants
     ●Quinolines
     ●Selective glucocorticoid receptor modulators
     ●Trifluoromethyl compounds
     ●Musculoskeletal system drug stubs
     ●Antineoplastic and immunomodulating drug stubs
     ●Dermatologic drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed ChemSpider identifier
     ●Articles with changed KEGG identifier
     ●ECHA InfoCard ID from Wikidata
     ●Articles with changed InChI identifier
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Drugboxes which contain changes to verified fields
     ●Articles containing potentially dated statements from January 2017
     ●All articles containing potentially dated statements
     ●All stub articles
      


    ●This page was last edited on 22 January 2023, at 20:00 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki